Discrete Element Method Modeling EDEM Software

The U.S. Food and Drug Administration (FDA), specifically the Center for Drug Evaluation and Research, is seeking to procure a software license for EDEM or an equivalent Discrete Element Method (DEM) modeling and simulation platform. The solicitation requires a comprehensive software package that includes capabilities for transient modeling of mixing processes, physical property calculations, and process optimization with a sophisticated DEM solver compatible with multi-core workstations and GPU systems. The procurement will be conducted as a Full and Open Competition using the Lowest Price Technically Acceptable (LPTA) evaluation method, with quotes due by May 14, 2025, at 1:00 PM EST. Potential vendors must be authorized resellers and provide detailed pricing information, along with a Unique Entity Identifier (UEI). Questions from interested parties will be accepted until May 7, 2025, and vendors must comply with federal acquisition regulations for commercial items and services.

The contract is classified under NAICS category 541519 (Other Computer Related Services) and PSC category 7A20 (IT and Telecom - Application Development Software), with no specific set-aside designations. The procurement is for one software license with a base year and four additional one-year option periods, spanning from June 8, 2025, to June 7, 2030. The place of performance is located in Silver Spring, MD 20993, and the contract will be executed as a Firm Fixed Price purchase order. While specific award values are not explicitly stated, the solicitation indicates a requirement for a single software license with comprehensive modeling and simulation capabilities. The procurement aims to secure a cutting-edge software solution that will support the FDA's research and evaluation processes in drug development and related scientific applications.